Recombinant Human Retinoic acid-induced protein 3 (GPRC5A)

What is GPRC5A and what cellular pathways is it involved in?

GPRC5A is a member of the 'Retinoic Acid-Inducible G-protein-coupled receptors' (RAIG) group, which consists of four orphan receptors: GPRC5A, GPRC5B, GPRC5C, and GPRC5D. As the name suggests, its expression is induced by retinoic acid. The protein is involved in several cellular pathways, particularly those related to tumor development and progression . Recent research using Gene Set Enrichment Analysis (GSEA) has revealed that GPRC5A is primarily associated with neutrophil degranulation, signaling by interleukins, GPCR ligand binding, and the RHO GTPase cycle . These pathways suggest GPRC5A plays roles in both immune regulation and signal transduction across various cellular contexts.

How is the GPRC5A gene structurally organized and regulated at the transcriptional level?

The GPRC5A gene contains a novel retinoic acid response element (RARE) at its proximal 5′ upstream region. In the absence of retinoic acid, retinoic acid receptors bind to this RARE as RAR/RXR heterodimers, recruiting co-repressor proteins and repressing GPRC5A gene transcription. When agonist ligands bind to RAR/RXRs, co-repressors dissociate and co-activator proteins are recruited, promoting GPRC5A gene transcription .

Additionally, the GPRC5A gene locus contains p53 consensus DNA binding sequences in the promoter region. Wild-type p53 has been shown to repress GPRC5A expression, while p53 mutations lead to increased GPRC5A levels in cancer cells. The promoter region also contains a cAMP-responsive element (CRE), allowing GPRC5A expression to be induced by cAMP signaling. Interestingly, cAMP and retinoic acid might synergistically regulate GPRC5A expression .

What is the expression pattern of GPRC5A across different cancer types?

GPRC5A shows variable expression patterns across different cancer types. According to comprehensive analyses of 33 tumor datasets from TCGA and GTEx databases, GPRC5A is differentially expressed between tumor and normal tissues in multiple cancer types .

The following table summarizes GPRC5A dysregulation in various diseases:

This expression pattern heterogeneity suggests context-dependent roles for GPRC5A across different malignancies .

How does GPRC5A function as both a tumor suppressor and an oncogene?

GPRC5A exhibits a dual-behavior pattern, functioning as either a tumor suppressor or an oncogene depending on the cancer type and cellular context. This dual behavior makes GPRC5A particularly interesting in cancer research .

As a tumor suppressor:

• In lung cancer, loss of GPRC5A has been associated with increased tumor development

• Its expression can inhibit cell proliferation and promote apoptosis in certain cellular contexts

As an oncogene:

• In breast cancer with p53 mutations, GPRC5A is upregulated and promotes tumor growth

• In colorectal adenocarcinoma, higher expression is associated with disease recurrence

• In pancreatic cancer, it appears to promote cancer cell survival and proliferation

This context-dependent function likely depends on:

• The specific signaling environment in different tissues

• Genetic background (particularly p53 status)

• Interaction with tissue-specific transcription factors

• Differential regulation by microRNAs across tissue types

What is the prognostic value of GPRC5A expression in cancer?

GPRC5A has demonstrated significant prognostic value across several cancer types. In a comprehensive meta-analysis, GPRC5A expression was evaluated for its relationship with cancer prognosis across multiple studies .

In colorectal cancer specifically, RAI3 (GPRC5A) overexpression has been identified as a potential prognostic marker. A study analyzing 367 colorectal cancer tissue samples found that a subset of patients (7.4%) displayed very strong cytoplasmic expression of RAI3, which was significantly associated with disease recurrence in Dukes' A-C (stage I-III) patients with a hazard ratio of 3.076 (95% CI=1.738-5.445; p<0.001) compared to low or negative expression .

This association retained univariate significance in Dukes' B/stage II patients only (HR=3.494, 95% CI=1.197-10.20; p<0.022). Critically, the prognostic capacity of RAI3 was maintained in the stage I-III cohort following multivariate modeling (HR=2.11, 95% CI 1.109-4.017, p=0.023) .

More recent research has expanded the prognostic evaluation of GPRC5A to multiple cancer types, including adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), low-grade glioma (LGG), and pancreatic adenocarcinoma (PAAD), where its expression was found to be prognostically significant .

What post-transcriptional mechanisms regulate GPRC5A expression?

MicroRNAs (miRNAs) play a significant role in the post-transcriptional regulation of GPRC5A. While this area is still being explored, some important findings include:

• miR-103a-3p has been shown to target the 5′UTR of GPRC5A mRNA in pancreatic cells, which is particularly noteworthy as miRNA targeting of 5′UTRs leading to mRNA down-regulation is relatively rare

• Overexpression of miR-103a-3p reduces both GPRC5A mRNA and protein in cells

• Computational predictions using the rna22 algorithm suggest many other putative miRNA target sites throughout the GPRC5A mRNA

The table below shows the number of distinct miRBase miRNAs and target sites that rna22 predicts target GPRC5A (P-val ≤ 0.05):

RNA binding proteins (RBPs) and long non-coding RNAs (lncRNAs) are also suspected to post-transcriptionally regulate GPRC5A, though concrete data is currently limited .

How does the p53 pathway influence GPRC5A expression?

The relationship between p53 and GPRC5A is particularly significant in cancer research. The GPRC5A gene locus contains p53 consensus DNA binding sequences in the promoter region. Studies have shown that:

• Overexpression of wild-type p53 represses GPRC5A expression in the 2774qw1 human ovarian tumor cell line

• Microarray and quantitative RT-PCR analyses in multiple breast cancer cell lines demonstrate that GPRC5A mRNA is up-regulated in p53-mutated cell lines

• Cell lines with mutant p53 (MDA-MB-468, BT-20, BT-549, and SK-BR-3) show higher GPRC5A expression compared to those with wild-type p53 (T47D, MCF7, ZR-75-1, and BT474)

This regulatory relationship suggests that GPRC5A dysregulation in cancers may be partly due to the common occurrence of p53 mutations, which release the suppressive effect of wild-type p53 on GPRC5A expression .

What are the most effective methods for detecting and measuring GPRC5A expression in tissue samples?

Researchers have employed several complementary techniques to detect and quantify GPRC5A expression:

• Immunohistochemistry (IHC): This technique has been widely used to evaluate GPRC5A protein expression in various cancer tissues. IHC allows visualization of protein expression patterns within the cellular context, revealing that GPRC5A can show diffuse cytoplasmic expression in cancer cells. In colorectal cancer, 76% of cases displayed diffuse cytoplasmic expression, with 7.4% showing very strong expression .

• Microarray analysis: This approach has been employed to analyze GPRC5A mRNA expression across multiple tumor types and can be used for large-scale screening .

• Quantitative RT-PCR (qRT-PCR): This method provides more precise quantification of GPRC5A mRNA levels and has been used to validate microarray findings in several studies .

• Next-Generation Sequencing (NGS): This technique allows for comprehensive analysis of gene expression and has been applied to study GPRC5A in breast carcinoma .

• Mass spectrometry-based proteomics: Label-free mass spectrometric (MS) quantitation has been successfully used to identify GPRC5A/RAI3 as a plasma membrane protein overexpressed in colorectal cancer .

• Western blotting (WB): This technique has been utilized for protein-level confirmation of GPRC5A expression in hepatocellular carcinoma .

For optimal results, researchers should consider using multiple complementary techniques, as each provides different insights into GPRC5A expression.

How can researchers effectively study GPRC5A's interactions with the immune microenvironment?

The interaction between GPRC5A and the tumor immune microenvironment has emerged as an important area of research. To effectively study these interactions, researchers can employ the following approaches:

• Correlation analysis between GPRC5A expression and immune cell infiltration: Using databases like GEPIA2, researchers can analyze the relationship between GPRC5A expression and various immune cells, including B cells, macrophages, and neutrophils. Heatmaps can be generated to visualize these correlations across multiple cancer types .

• Gene Set Enrichment Analysis (GSEA): This method can identify biological pathways associated with GPRC5A expression, particularly immune-related pathways. Recent GSEA has revealed that GPRC5A is primarily associated with neutrophil degranulation and signaling by interleukins .

• Immunohistochemical co-staining: This technique allows for simultaneous visualization of GPRC5A expression and immune cell markers in tissue samples, providing spatial information about their relationship.

• Single-cell RNA sequencing: This advanced approach can reveal cell-type-specific expression patterns and interactions between GPRC5A-expressing cells and immune cells.

• In vitro co-culture systems: Researchers can establish co-cultures of GPRC5A-expressing cancer cells with various immune cell populations to study their functional interactions.

• Cytokine profiling: Measuring cytokine production in the presence of varying GPRC5A expression levels can provide insights into how GPRC5A influences the immune microenvironment.

These methods collectively can provide a comprehensive understanding of how GPRC5A modulates the tumor immune microenvironment across different cancer types.

What are the key challenges in developing GPRC5A-targeted therapies?

Developing therapies targeting GPRC5A presents several significant challenges:

• Dual functional behavior: GPRC5A can function as either a tumor suppressor or an oncogene depending on the cancer type and cellular context. This dual nature necessitates careful consideration of cancer-specific targeting strategies to avoid unintended consequences .

• Tissue-specific expression patterns: GPRC5A expression varies significantly across different tissues and cancer types, requiring tissue-specific targeting approaches .

• Orphan receptor status: As an orphan receptor, GPRC5A lacks identified endogenous ligands, complicating the development of compounds that could modulate its activity. Identifying natural or synthetic ligands remains a critical research gap.

• Complex regulatory mechanisms: GPRC5A is regulated at multiple levels (transcriptional, post-transcriptional) by various factors including retinoic acid, p53, cAMP, and miRNAs. This complex regulation makes it challenging to predict the effects of therapeutic interventions .

• Interaction with the immune microenvironment: GPRC5A's involvement in modulating the immune microenvironment adds another layer of complexity to therapeutic development, as interventions might have indirect effects on immune responses .

• Limited understanding of downstream signaling: While GPRC5A is involved in GPCR ligand binding and the RHO GTPase cycle, the complete picture of its downstream signaling networks remains incomplete, hampering rational drug design .

Addressing these challenges requires integrative approaches combining structural biology, drug discovery, cancer biology, and immunology to develop effective GPRC5A-targeted therapeutic strategies.

How can GPRC5A expression be integrated with other biomarkers for improved cancer prognosis?

Integrating GPRC5A with other biomarkers offers significant potential for enhancing cancer prognosis prediction:

• Multivariate prognostic models: Researchers have demonstrated that GPRC5A retains prognostic significance in multivariate models. For colorectal cancer, GPRC5A/RAI3 maintained prognostic capacity in stage I-III patients following multivariate modeling (HR=2.11, 95% CI 1.109-4.017, p=0.023), suggesting it can complement existing prognostic factors .

• Nomogram development: Developing nomogram models that incorporate GPRC5A expression alongside clinical parameters can improve survival probability predictions. Such models have been explored for various cancer types where GPRC5A has prognostic value .

• Immune signature integration: Given GPRC5A's correlation with immune cell infiltration, combining GPRC5A expression with immune signature markers could provide more comprehensive prognostic information, particularly regarding immunotherapy response .

• Molecular subtyping: Integrating GPRC5A expression into molecular subtyping schemes could help refine cancer classification and improve treatment stratification.

• Multi-omics approaches: Combining GPRC5A expression data with genomic, transcriptomic, proteomic, and metabolomic profiles could yield more robust prognostic signatures across different cancer types.

• AI-based prediction models: Developing machine learning algorithms that incorporate GPRC5A alongside other biomarkers could enhance prognostic accuracy and identify patients most likely to benefit from specific therapeutic interventions.

Future research should focus on validating these integrated approaches in large, prospective cohorts across multiple cancer types to establish their clinical utility.